REGKIRONA 60mg/ml concentrate for solution for infusion NUVISAN GMBH
Chemical substance: regdanvimab
ATC code: J06BD06 • Antiinfectives for systemic use | Immunoglobulins | Antiviral monoclonal antibodies
Active substance
Results for the substance regdanvimab
1 result
About this active substance
Regdanvimab is a monoclonal antibody used for the treatment of SARS-CoV-2 infection in patients with mild to moderate COVID-19 who are at high risk of progressing to severe disease. It works by binding to the virus's spike protein, preventing its entry into cells.
The medication is administered intravenously, as directed by a doctor, usually as a single infusion. It is important for patients to be monitored for adverse reactions during and after administration.
Patients should be aware of potential side effects, such as injection site reactions, fever, or allergic reactions. It is important to inform the doctor of any unusual symptoms.
Common side effects include injection site reactions, fever, and nausea. In rare cases, severe reactions such as anaphylactic reactions may occur. Patients should be informed of these risks before use.
The medication is administered intravenously, as directed by a doctor, usually as a single infusion. It is important for patients to be monitored for adverse reactions during and after administration.
Patients should be aware of potential side effects, such as injection site reactions, fever, or allergic reactions. It is important to inform the doctor of any unusual symptoms.
Common side effects include injection site reactions, fever, and nausea. In rare cases, severe reactions such as anaphylactic reactions may occur. Patients should be informed of these risks before use.